Leslie Shaw to Immunosuppressive Agents
This is a "connection" page, showing publications Leslie Shaw has written about Immunosuppressive Agents.
Connection Strength
4.422
-
Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010 Jul 15; 90(1):31-7.
Score: 0.295
-
Bullock JM, Smith PF, Booker BM, Loughner J, Capozzi D, McCarthy PL, Shaw LM. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 2006 Feb; 28(1):62-6.
Score: 0.217
-
van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S244-53.
Score: 0.212
-
Venkataramanan R, Shaw LM. Therapeutic monitoring of mycophenolic acid in liver transplant patients. Liver Transpl. 2004 Apr; 10(4):503-5.
Score: 0.191
-
McKaig SJ, Kelly D, Shaw L. Investigation of the effect of FK506 (tacrolimus) and cyclosporin on gingival overgrowth following paediatric liver transplantation. Int J Paediatr Dent. 2002 Nov; 12(6):398-403.
Score: 0.173
-
Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001 Aug; 23(4):305-15.
Score: 0.158
-
DeNofrio D, Loh E, Kao A, Korecka M, Pickering FW, Craig KA, Shaw LM. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000 Nov; 19(11):1071-6.
Score: 0.150
-
Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem. 2000 Jun; 46(6 Pt 1):872-4.
Score: 0.146
-
Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000 Jun; 40(6):624-33.
Score: 0.146
-
Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000 Feb; 22(1):14-9.
Score: 0.143
-
Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999 Oct; 21(10):1632-52; discussion 1631.
Score: 0.140
-
Korecka M, Nikolic D, van Breemen RB, Shaw LM. The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Clin Chem. 1999 Jul; 45(7):1047-50.
Score: 0.137
-
Shaw LM, Korecka M, Aradhye S, Grossman R, Barker C, Naji A, Brayman KL. Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant Proc. 1998 Aug; 30(5):2234-6.
Score: 0.129
-
Oellerich M, Armstrong VW, Sch?tz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem. 1998 Jul; 31(5):309-16.
Score: 0.128
-
Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem. 1998 Jul; 31(5):317-22.
Score: 0.128
-
Shaw LM, Korecka M, van Breeman R, Nowak I, Brayman KL. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem. 1998 Jul; 31(5):323-8.
Score: 0.128
-
Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998 Apr 27; 65(8):1127-9.
Score: 0.126
-
Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998 Mar; 38(3):268-75.
Score: 0.125
-
Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
Score: 0.124
-
Shaw LM. Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. Drug Metabol Drug Interact. 1997; 14(1):33-40.
Score: 0.115
-
Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996 Aug; 42(8 Pt 2):1316-21.
Score: 0.112
-
Shaw LM, Annesley TM, Kaplan B, Brayman KL. Analytic requirements for immunosuppressive drugs in clinical trials. Ther Drug Monit. 1995 Dec; 17(6):577-83.
Score: 0.107
-
Shaw LM, Sollinger HW, Halloran P, Morris RE, Yatscoff RW, Ransom J, Tsina I, Keown P, Holt DW, Lieberman R, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit. 1995 Dec; 17(6):690-9.
Score: 0.107
-
Yatscoff RW, Shaw LM. Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. Ther Drug Monit. 1992 Aug; 14(4):267-8.
Score: 0.085
-
de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009 Dec; 36(6):541-64.
Score: 0.070
-
Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
Score: 0.068
-
van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009; 48(7):463-76.
Score: 0.066
-
Schubert M, Venkataramanan R, Holt DW, Shaw LM, McGhee W, Reyes J, Webber S, Sindhi R. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant. 2004 May; 4(5):767-73.
Score: 0.048
-
Sindhi R, Webber S, Goyal R, Reyes J, Venkataramanan R, Shaw L. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. Transplant Proc. 2002 Aug; 34(5):1960.
Score: 0.042
-
Terrell AR, Daly TM, Hock KG, Kilgore DC, Wei TQ, Hernandez S, Weibe D, Fields L, Shaw LM, Scott MG. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer. Clin Chem. 2002 Jul; 48(7):1059-65.
Score: 0.042
-
Hosey MT, Davison SM, Gordon G, Shaw L, Kelly DA. Cytomegalovirus and cyclosporin-induced gingival overgrowth in children with liver grafts. Int J Paediatr Dent. 2002 Jul; 12(4):236-43.
Score: 0.042
-
Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002 Feb; 24(1):59-67.
Score: 0.041
-
Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001 May; 41(5):542-51.
Score: 0.039
-
Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001 Feb; 34(1):17-22.
Score: 0.038
-
Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, Silberstein LE, Nowell PC, Schuler W, Shaw LM, Wasik MA. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4285-90.
Score: 0.036
-
Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000 Feb; 22(1):27-30.
Score: 0.036
-
MacFarlane GD, Shaw LM, Venkataramanan R, Mullins R, Scheller DG, Ersfeld DL. Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function. Ther Drug Monit. 1999 Dec; 21(6):585-92.
Score: 0.035
-
MacFarlane GD, Scheller DG, Ersfeld DL, Shaw LM, Venkatarmanan R, Sarkozi L, Mullins R, Fox BR. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. Clin Chem. 1999 Sep; 45(9):1449-58.
Score: 0.035
-
Shipkova M, Niedmann PD, Armstrong VW, Sch?tz E, Wieland E, Shaw LM, Oellerich M. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998 Jul; 44(7):1481-8.
Score: 0.032
-
Schulman SL, Shaw LM, Jabs K, Leonard MB, Brayman KL. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation. 1998 May 27; 65(10):1397-8.
Score: 0.032
-
Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. Transplant Proc. 1997 Dec; 29(8):3669-70.
Score: 0.031
-
Salm P, Taylor PJ, Clark A, Balderson GA, Grygotis A, Norris RL, Lynch SV, Shaw LM, Pond SM. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. Ther Drug Monit. 1997 Dec; 19(6):694-700.
Score: 0.031
-
Weber M, Ketchum RJ, Sellers M, Aradhye S, Deng S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. Transplant Proc. 1997 Feb-Mar; 29(1-2):338-9.
Score: 0.029
-
Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995 Dec; 17(6):642-54.
Score: 0.027
-
Hosey MT, Gordon G, Kelly DA, Shaw L. Oral findings in children with liver transplants. Int J Paediatr Dent. 1995 Mar; 5(1):29-34.
Score: 0.025
-
Shaw LM, Bonner HS, Fields L, Lieberman R. The use of concentration measurements of parent drug and metabolites during clinical trials. Ther Drug Monit. 1993 Dec; 15(6):483-7.
Score: 0.023
-
Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008 Mar 27; 85(6):821-6.
Score: 0.016
-
van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006 Apr; 28(2):145-54.
Score: 0.014